Veterinary Fungal Vaccine Development

Fungi are ubiquitous in the environment, like bacteria, fungi can infect animals and threaten human health as well. Animal fungal diseases are classified as primary and opportunistic, occurring in hosts with normal or compromised immunity, respectively. Antifungal drugs are often expensive and have a long duration of use. BioVenic provides animal fungal vaccine development services in anticipation of helping to solve problems not addressed by traditional antifungal drugs, particularly for invasive fungal diseases in livestock, poultry, aquaculture species, and companion animals.

Veterinary Fungal Vaccine Development

Veterinary fungal vaccines play a role in maintaining the health of livestock and companion animals, preventing possible fungal diseases and minimizing the impact that fungal infections may have on animals at the source. The three main types of veterinary fungal vaccines under development are live attenuated vaccines, recombinant subunit vaccines and conjugate vaccines, as well as pan-fungal vaccines with broad-spectrum antifungal capabilities. BioVenic has established the several veterinary fungal vaccine development platforms to help you win the battle against animal fungi.

Veterinary Pan-Fungal Vaccine Development

Pan-fungal vaccine is a broad-spectrum vaccine. It utilizes antigens shared by fungi to induce the host immune system to mount an immune response against multiple fungi, thereby providing more comprehensive protection against multiple fungal infections in animals. The development of pan-fungal vaccines requires the integration of the characteristics of multiple fungal species to ensure that the vaccine is able to generate an effective immune response under different circumstances. BioVenic offers research and development services to help meet your fungal challenges through careful antigen selection and vaccine formulation development.

Our Services

Fungal Identification

Fungal Identification is the pivotal step within our veterinary fungal vaccine development services. BioVenic offers specialized fungal identification services to precisely define the fungal pathogens relevant to your vaccine development. Our comprehensive approaches combine advanced genetic sequencing, morphological analysis, and molecular techniques, ensuring accurate and species-specific identification. This crucial service lays the groundwork for targeted vaccine design.

Veterinary Fungal Vaccine Development Platforms

BioVenic has established comprehensive vaccine development platforms, which enable to provide routine veterinary fungal vaccine development services to satisfy your research requirements.

• Live Attenuated Veterinary Fungal Vaccine Development
  Based on the similarity of live attenuated vaccines to pathogens, they produce a prolonged and strong immune response and are effective in immunocompetent animals. The first live attenuated veterinary fungal vaccine, designed to prevent ringworm caused by Trichophyton verrucosum in cattle, demonstrated the effectiveness of the immunization-immunoprophylaxis strategy.
  BioVenic has established a platform for live attenuated veterinary fungal vaccine development, starting with attenuation and focusing on their safety to prevent their improper use in animals.
• Recombinant Subunit Veterinary Fungal Vaccine Development
  Recombinant subunit vaccine is a well-studied type of veterinary fungal vaccine consisting of one or more purified recombinant proteins or polysaccharides. The antigen is usually paired with an appropriate adjuvant to establish an effective immune response and prolong immunity. Safety is assured because of the absence of an intact pathogen.
  BioVenic provides elaborate subunit vaccine design, purification and manufacturing services to produce highly specialized antigens.
• Conjugate Veterinary Fungal Vaccine Development
  The major components of fungal cell walls and pod membranes are polysaccharides, and fungus-specific antibodies against surface polysaccharides and other antigens can mediate protection. Conjugate veterinary fungal vaccines are produced by covalently linking weak antigens, which are usually polysaccharides attached to strong protein antigens, to strong antigens, which enhances the effectiveness and stability of vaccines.
  BioVenic provides conjugate vaccine development services and carrier proteins according to your requirements. We have strict quality control to minimize batch-to-batch variation and ensure vaccine protection.
• Dendritic Cell-Based Veterinary Fungal Vaccine Development
  Dendritic cells have the unique ability to develop antifungal immunity by initiating and modulating the initial T-cell response, and thus targeting dendritic cells may yield effective vaccines against animal fungi. Dendritic cell-based vaccine involves culturing or "pulsing" dendritic cells (DCs) in vitro with specific antigens or pathogens, and then reintroducing these cells into the host to enhance protection against infectious agents.
  BioVenic exploited the unique immunomodulatory capacity of dendritic cells to produce targeted fungal vaccines. Through precise antigen loading and dendritic cell activation, we are committed to cultivate robust immune responses against animal fungal infections. We provide dendritic cell culture services and help you find receptor-related targets of dendritic cells to enhance its immune effect.

Fig.1 DC-based strategies for developing anti-fungal vaccines.¹

Our Advantages

BioVenic offers highly effective and safe vaccine development solutions designed to combat challenging fungal diseases among livestock, poultry, companion animals, aquaculture species and more. Feel free to contact us at any time and let's work together to safeguard the health and well-being of animals.

Reference

1. Roy, René M., and Bruce S. Klein. "Dendritic cells in antifungal immunity and vaccine design." Cell host & microbe 11.5 (2012): 436-446.